Compare RBBN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | REPL |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.1M | 721.7M |
| IPO Year | 2000 | 2018 |
| Metric | RBBN | REPL |
|---|---|---|
| Price | $2.89 | $9.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | 700.0K | ★ 1.6M |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $868,592,000.00 | N/A |
| Revenue This Year | $5.02 | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.38 | N/A |
| 52 Week Low | $2.72 | $2.68 |
| 52 Week High | $5.38 | $14.80 |
| Indicator | RBBN | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 55.27 |
| Support Level | $2.86 | $9.50 |
| Resistance Level | $3.00 | $10.29 |
| Average True Range (ATR) | 0.10 | 0.59 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 48.44 | 27.75 |
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.